Advances in Small-Cell Lung Cancer: Recognizing the Potential of Immune Checkpoint Inhibitors and Antibody–Drug Conjugates

Review key data and expert commentary on new agents and where they fit into the optimal management of patients with SCLC with these downloadable slides and expert-authored module developed by Anna F. Farago, MD, PhD; Matthew D. Hellmann, MD; and Taofeek K. Owonikoko, MD, PhD, MSCR.
D. Ross Camidge, MD, PhD
Anna F. Farago, MD, PhD
Matthew D. Hellmann, MD
Daniel Morgensztern, MD
Taofeek K. Owonikoko, MD, PhD


In this CME/CE/CPE-certified activity, Anna F. Farago, MD, PhD; Matthew D. Hellmann, MD; and Taofeek K. Owonikoko, MD, PhD, discuss practical considerations regarding the use of immune checkpoint inhibitors and antibody–drug conjugates in the treatment of patients with small-cell lung cancer.

Anna F. Farago, MD, PhD Matthew D. Hellmann, MD Taofeek K. Owonikoko, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: October 24, 2017 Expired: October 23, 2018

Downloadable Slideset

In this downloadable slideset, Anna F. Farago, MD, PhD; Matthew D. Hellmann, MD; and Taofeek K. Owonikoko, MD, PhD, review key data on immunotherapy and antibody–drug conjugates in SCLC.

Released: October 24, 2017


Second-line therapy options are limited for advanced SCLC. Are immunotherapy regimens safe and efficacious enough to consider for this patient population?

D. Ross Camidge, MD, PhD Released: September 13, 2017

Rova-T achieved high response rates in a phase I clinical trial of patients with recurrent SCLC, particularly those with high DLL3 expression. Here’s my take on the promise of Rova T in this patient population.

Daniel Morgensztern, MD Released: November 3, 2017
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

This activity is supported by educational grants from
Bristol-Myers Squibb

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?